TRANSPLANTATION BENEFIT of belatacept: kidney transplantation moves forward

被引：9

作者：

Naesens, Maarten ^{[1
]}

Thaunat, Olivier ^{[2
]}

机构：

[1] KU Leuven Univ Leuven, Dept Microbiol & Immunol, Herestr 49, B-3000 Leuven, Belgium

[2] Hop Edouard Herriot, HCL, Dept Transplantat Nephrol & Clin Immunol, 5 Pl Arsonval, F-69003 Lyon, France

来源：

NATURE REVIEWS NEPHROLOGY | 2016年 / 12卷 / 05期

关键词：

PHASE-III; CYCLOSPORINE; RECIPIENTS; EXTENSION;

D O I：

10.1038/nrneph.2016.34

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

New data from the BENEFIT study demonstrate that belatacept improves long-term allograft and patient survival after kidney transplantation, despite higher rates of biopsy-proven acute rejection than with ciclosporin. The noninferiority design of BENEFIT represents a feasible strategy to further the development of innovator drugs to reduce late graft loss.

引用

页码：261 / 262

页数：2

共 10 条

[1] Summary of the US FDA Approval of Belatacept [J].

Archdeacon, P. ;

Dixon, C. ;

Belen, O. ;

Albrecht, R. ;

Meyer, J. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (03) :554-562

[2] A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study) [J].

Durrbach, A. ;

Pestana, J. M. ;

Pearson, T. ;

Vincenti, F. ;

Garcia, V. D. ;

Campistol, J. ;

del Carmen Rial, M. ;

Florman, S. ;

Block, A. ;

Di Russo, G. ;

Xing, J. ;

Garg, P. ;

Grinyo, J. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (03) :547-557

[3] Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies [J].

Halloran, Philip F. ;

Reeve, Jeff P. ;

Pereira, Andre B. ;

Hidalgo, Luis G. ;

Farnulski, Konrad S. .

KIDNEY INTERNATIONAL, 2014, 85 (02) :258-264

[4] Organ Transplantation 2 Prevention of cardiovascular disease in adult recipients of kidney transplants [J].

Jardine, Alan G. ;

Gaston, Robert S. ;

Fellstrom, Bengt C. ;

Holdaas, Hallvard .

LANCET, 2011, 378 (9800) :1419-1427

[5] Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal [J].

Lamb, K. E. ;

Lodhi, S. ;

Meier-Kriesche, H. -U .

AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (03) :450-462

[6] Reporting of Noninferiority and Equivalence Randomized Trials Extension of the CONSORT 2010 Statement [J].

Piaggio, Gilda ;

Elbourne, Diana R. ;

Pocock, Stuart J. ;

Evans, Stephen J. W. ;

Altman, Douglas G. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (24) :2594-2604

[7] Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study [J].

Rostaing, L. ;

Vincenti, F. ;

Grinyo, J. ;

Rice, K. M. ;

Bresnahan, B. ;

Steinberg, S. ;

Gang, S. ;

Gaite, L. E. ;

Moal, M-C ;

Mondragon-Ramirez, G. A. ;

Kothari, J. ;

Pupim, L. ;

Larsen, C. P. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (11) :2875-2883

[8] The Elephant in the Room: Failings of Current Clinical Endpoints in Kidney Transplantation [J].

Schold, J. D. ;

Kaplan, B. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) :1163-1166

[9] A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) [J].

Vincenti, F. ;

Charpentier, B. ;

Vanrenterghem, Y. ;

Rostaing, L. ;

Bresnahan, B. ;

Darji, P. ;

Massari, P. ;

Mondragon-Ramirez, G. A. ;

Agarwal, M. ;

Di Russo, G. ;

Lin, C. -S. ;

Garg, P. ;

Larsen, C. P. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (03) :535-546

[10] Belatacept and Long-Term Outcomes in Kidney Transplantation [J].

Vincenti, Flavio ;

Rostaing, Lionel ;

Grinyo, Joseph ;

Rice, Kim ;

Steinberg, Steven ;

Gaite, Luis ;

Moal, Marie-Christine ;

Mondragon-Ramirez, Guillermo A. ;

Kothari, Jatin ;

Polinsky, Martin S. ;

Meier-Kriesche, Herwig-Ulf ;

Munier, Stephane ;

Larsen, Christian P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :333-343

← 1 →